5-(1,1-dioxido-1,2-thiazinan-2-yl)-N'-(2-(4-fluorophenyl)acetyl)-8-methoxy-1,6-naphthyridine-7-carbohydrazide | 1153775-05-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-(1,1-dioxido-1,2-thiazinan-2-yl)-N'-(2-(4-fluorophenyl)acetyl)-8-methoxy-1,6-naphthyridine-7-carbohydrazide
• CAS: 1153775-05-3
• 化学式: C₂₂H₂₂FN₅O₅S
• 分子量: 487.512
• InChiKey: IIFPXWOITWOXBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.71
• 重原子数：
  34.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  130.59
• 氢给体数：
  2.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  5-(1,1-dioxido-1,2-thiazinan-2-yl)-N'-(2-(4-fluorophenyl)acetyl)-8-methoxy-1,6-naphthyridine-7-carbohydrazide 在 碘 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 以56%的产率得到2-(7-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-8-methoxy-1,6-naphthyridin-5-yl)-1,2-thiazinane 1,1-dioxide
  参考文献：
  名称：

  The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore

  摘要：

  A series of HIV-1 integrase inhibitors containing a novel metal binding motif consisting of the 8-hydroxy1,6-naphthyridine core and either an oxadiazole or triazole has been identified. The design of the key structural components was based on a two-metal coordination pharmacophore. This report presents initial structure-activity data that shows the new chelation architecture delivers potent inhibition in both enzymatic and antiviral assays. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.090
• 作为产物：
  描述：

  5-(1,1-dioxido-1,2-thiazinan-2-yl)-8-methoxy-1,6-naphthyridine-7-carboxylic acid 、 对氟苯乙酰肼 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以90%的产率得到5-(1,1-dioxido-1,2-thiazinan-2-yl)-N'-(2-(4-fluorophenyl)acetyl)-8-methoxy-1,6-naphthyridine-7-carbohydrazide
  参考文献：
  名称：

  The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore

  摘要：

  A series of HIV-1 integrase inhibitors containing a novel metal binding motif consisting of the 8-hydroxy1,6-naphthyridine core and either an oxadiazole or triazole has been identified. The design of the key structural components was based on a two-metal coordination pharmacophore. This report presents initial structure-activity data that shows the new chelation architecture delivers potent inhibition in both enzymatic and antiviral assays. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.090